INSTABILITY OF EFAVIRENZ METABOLITES IDENTIFIED DURING METHOD DEVELOPMENT AND VALIDATION.

[1]  D. Haas,et al.  Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites , 2018, The Journal of antimicrobial chemotherapy.

[2]  A. Telenti,et al.  In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid , 2016, Drug Metabolism and Disposition.

[3]  R. Altman,et al.  PharmGKB summary: Efavirenz pathway, pharmacokinetics , 2015, Pharmacogenetics and genomics.

[4]  M. Ashton,et al.  A rapid and selective HPLC-UV method for the quantitation of efavirenz in plasma from patients on concurrent HIV/AIDS and tuberculosis treatments. , 2013, Biomedical chromatography : BMC.

[5]  G. Maartens,et al.  Neuronal toxicity of efavirenz: a systematic review , 2013, Expert opinion on drug safety.

[6]  J. Barrett,et al.  A Sensitive and Selective Liquid Chromatography/Tandem Mass Spectrometry Method for Quantitative Analysis of Efavirenz in Human Plasma , 2013, PloS one.

[7]  Edward J. Mills,et al.  Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis , 2013, AIDS.

[8]  C. Hendrix,et al.  Compartmentalization and Antiviral Effect of Efavirenz Metabolites in Blood Plasma, Seminal Plasma, and Cerebrospinal Fluid , 2013, Drug Metabolism and Disposition.

[9]  J. McArthur,et al.  Dendritic Spine Injury Induced by the 8-Hydroxy Metabolite of Efavirenz , 2012, Journal of Pharmacology and Experimental Therapeutics.

[10]  Kwang-Hyeon Liu,et al.  Rapid and Simultaneous Determination of Efavirenz, 8-Hydroxyefavirenz, and 8,14-Dihydroxyefavirenz Using LC–MS–MS in Human Plasma and Application to Pharmacokinetics in Healthy Volunteers , 2011 .

[11]  I. Kanfer,et al.  Rapid method for the quantitative determination of efavirenz in human plasma. , 2009, Journal of pharmaceutical and biomedical analysis.

[12]  J. Mallolas,et al.  Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[13]  A. Telenti,et al.  Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .

[14]  A. Mutlib,et al.  Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[15]  J. Ribeiro,et al.  Ultra-performance liquid chromatographic method for simultaneous quantification of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors in human plasma , 2011 .